Back to Search
Start Over
Research progress in immune checkpoint inhibitors for lung cancer in China
- Source :
- Therapeutic Advances in Medical Oncology, Vol 13 (2021), Therapeutic Advances in Medical Oncology
- Publication Year :
- 2021
- Publisher :
- SAGE Publishing, 2021.
-
Abstract
- Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a first-line treatment for late-stage non-small-cell lung cancer, either as a monotherapy or in combination with chemotherapy. Accordingly, the indications of Food and Drug Administration-approved ICIs have increased. In this background, China has implemented various policies to encourage and accelerate the marketing of domestic and imported innovative antitumor drugs. Eight ICIs have been approved in China. Among these, four imported programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have received approval for six indications, and one domestic PD-1 inhibitor has received approval for one indication for lung cancer in 2018. Numerous clinical trials of ICIs for lung cancer are underway in China. This review aims to summarize the recent advances and future directions of ICIs, including PD-1 inhibitors, PD-L1 inhibitors, cytotoxic T lymphocyte-associated antigen-4 inhibitors, bi-specific antibodies, and a novel inhibitor of T-cell immune-receptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains in immunotherapies for lung cancer in China.
- Subjects :
- 0301 basic medicine
Oncology
Drug
medicine.medical_specialty
China
medicine.medical_treatment
media_common.quotation_subject
Treatment of lung cancer
Review
immune checkpoint inhibitors
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Cytotoxic T cell
Lung cancer
RC254-282
media_common
Chemotherapy
biology
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunotherapy
medicine.disease
Clinical trial
lung cancer
030104 developmental biology
progress
030220 oncology & carcinogenesis
biology.protein
immunotherapy
Antibody
business
Subjects
Details
- Language :
- English
- ISSN :
- 17588359
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Medical Oncology
- Accession number :
- edsair.doi.dedup.....74f89273c64e54efa57568dc46300bfe